1. Home
  2. TEVA vs SNA Comparison

TEVA vs SNA Comparison

Compare TEVA & SNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TEVA
  • SNA
  • Stock Information
  • Founded
  • TEVA 1901
  • SNA 1920
  • Country
  • TEVA Israel
  • SNA United States
  • Employees
  • TEVA N/A
  • SNA N/A
  • Industry
  • TEVA Biotechnology: Pharmaceutical Preparations
  • SNA Industrial Machinery/Components
  • Sector
  • TEVA Health Care
  • SNA Consumer Discretionary
  • Exchange
  • TEVA Nasdaq
  • SNA Nasdaq
  • Market Cap
  • TEVA 18.4B
  • SNA 17.9B
  • IPO Year
  • TEVA N/A
  • SNA N/A
  • Fundamental
  • Price
  • TEVA $15.38
  • SNA $336.83
  • Analyst Decision
  • TEVA Strong Buy
  • SNA Buy
  • Analyst Count
  • TEVA 6
  • SNA 6
  • Target Price
  • TEVA $24.00
  • SNA $355.33
  • AVG Volume (30 Days)
  • TEVA 11.7M
  • SNA 423.5K
  • Earning Date
  • TEVA 05-07-2025
  • SNA 04-17-2025
  • Dividend Yield
  • TEVA N/A
  • SNA 2.54%
  • EPS Growth
  • TEVA N/A
  • SNA 4.00
  • EPS
  • TEVA N/A
  • SNA 19.51
  • Revenue
  • TEVA $16,544,000,000.00
  • SNA $5,108,400,000.00
  • Revenue This Year
  • TEVA $5.31
  • SNA N/A
  • Revenue Next Year
  • TEVA $1.18
  • SNA $4.20
  • P/E Ratio
  • TEVA N/A
  • SNA $17.27
  • Revenue Growth
  • TEVA 4.41
  • SNA 0.00
  • 52 Week Low
  • TEVA $12.51
  • SNA $252.98
  • 52 Week High
  • TEVA $22.80
  • SNA $373.90
  • Technical
  • Relative Strength Index (RSI)
  • TEVA 38.74
  • SNA 51.75
  • Support Level
  • TEVA $15.28
  • SNA $327.66
  • Resistance Level
  • TEVA $15.80
  • SNA $340.84
  • Average True Range (ATR)
  • TEVA 0.52
  • SNA 6.93
  • MACD
  • TEVA -0.01
  • SNA 0.83
  • Stochastic Oscillator
  • TEVA 30.41
  • SNA 78.40

About TEVA Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.

About SNA Snap-On Incorporated

Snap-on manufactures premium tools and software for repair professionals. Hand tools are sold through a franchisee-operated mobile van network that serve auto technicians who purchase tools at their own expense. A unique element of its business model is that franchisees bear significant risk, as they must invest in the mobile van, inventory, and software. At the same time, franchisees extend personal credit directly to technicians on an individual tool basis. Snap-on currently operates three segments: repair systems and information, commercial and industrial, and tools. Its finance arm provides financing to franchisees to run their operations, which includes offering loans and leases for mobile vans.

Share on Social Networks: